Neimeth International Pharmaceuticals plc announced earnings results for the year ended September 30, 2013. For the period, the company reported a turnover of NGN 2,017 billion as against NGN 1,519 billion (adjusted to 12 months) in 2012, showing a growth indices of 33%. With top line revenue of NGN 2,017 billion the company showed an impressive gross margin of NGN 642 million, a growth of 21% over 2012's NGN 529 million (adjusted to 12 months) Profit before tax showed a significant growth of 451%, NGN 183 million, against NGN 52 million in 2012.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 NGN | 0.00% | -8.11% | -12.37% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.37% | 4.95M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- NEIMETH Stock
- News Neimeth International Pharmaceuticals Plc
- Neimeth International Pharmaceuticals plc announces Earnings Results for the Year Ended September 30, 2013